Quantcast
Breast Cancer Drug Perjeta Shows Unprecedented Success In

Breast Cancer Drug Perjeta Shows 'Unprecedented' Success In Clinical Trials

Chuck Bednar for redOrbit.com - Your Universe Online Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to...

Latest Trastuzumab Stories

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the headline should read $3.8 billion rather than $3.8 million as originally issued inadvertently. The complete, corrected release follows: The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion...

2014-09-18 12:27:44

Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that the gastric cancer market will grow exponentially from over $1.1 billion in 2013 to nearly $3.8 billion by 2023. Fuelling this growth will be the launch of five targeted therapies for unresectable locally advanced and metastatic...

2014-08-20 08:27:31

MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody...

2014-07-02 16:24:20

ROCKVILLE, Md., July 2, 2014 /PRNewswire/ -- A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with support from the BBVA Foundation, defined for the first time a quantitative HER2 protein level measured by mass spectrometry is associated with longer disease free and overall survival in patients receiving anti-HER2 treatment. Results of the study were presented during the ASCO 2014 Annual...

2014-06-04 11:26:06

American Heart Association Study Highlights: -About 12 percent of older breast cancer patients developed heart failure within three years, often as a result of the cancer drugs and treatments. -Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems. -Those who saw a cardiologist were more likely to receive standard drugs for heart failure than those who didn’t. Only a third of older breast cancer patients saw a cardiologist...

2014-06-02 16:26:24

OAKLAND, Calif., June 2, 2014 /PRNewswire/ -- Patients with specific HER2+ breast cancer tumors have a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO Researchers reviewed 16,975 cases of breast cancer diagnosed in Kaiser Permanente patients between 2000 and 2006....

2014-05-22 10:49:08

CSH Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer. The breast cancer subtype in question is commonly called “HER2-positive”; it’s a subset of the disease affecting about one patient in four, in which tumor cells overexpress a signaling protein called HER2.  The blockbuster drug Herceptin is a first-line treatment for many women with...

2014-05-14 08:31:42

SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b The discovery that our Hemopurifer® captures tumor-secreted exosomes provides hope for a new therapeutic paradigm to augment cancer care. Yes, the same Hemopurifier® we are preparing to advance in a forthcoming FDA approved infectious disease study. In my last CEO note, I...

2014-04-23 12:29:08

WORCESTER, Mass. and TORONTO, April 23, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that two abstracts in respect of results of the on-going Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer will be presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 30 to June 3, 2014. The ASCO Annual Meeting is the...

2014-04-10 12:26:46

Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related